Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms"

Affiliations

• ¹ First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, [email protected].
• ² 251 HAF and VA Hospital, Athens, Greece, [email protected].
• ³ First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
• ⁴ Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
• ⁵ Department of Clinical Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland.
• ⁶ Oncology Department and Radiation Therapy Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
• ⁷ Neuroendocrine Tumor Unit, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
• ⁸ Department of Endocrinology and Neuroendocrine Neoplasms, Medical University of Silesia, Katowice, Poland.
• ⁹ Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, Poland.
• ¹⁰ Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.
• ¹¹ Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.